Lipella Pharmaceuticals Inc. (LIPO)
OTCMKTS · Delayed Price · Currency is USD
0.1400
-0.0300 (-17.65%)
May 20, 2026, 3:20 PM EST
Lipella Pharmaceuticals Company Description
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.
It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus.
The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Lipella Pharmaceuticals Inc.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jonathan Kaufman |
Contact Details
Address: 7800 Susquehanna St. Pittsburgh, Pennsylvania Pennsylvania United States | |
| Phone | 412 894 1853 |
Stock Details
| Ticker Symbol | LIPO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US53630L2097 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan Kaufman M.B.A., Ph.D. | Co-Founder, Chairman, Chief Executive Officer, President, Secretary and Treasurer |
| Douglas Johnston CPA | Chief Financial Officer |
| Michele Gruber | Director of Operations |
| Janet Okonski | Director of Clinical Operations |
| Katie Johnston | Controller |